Primary care physicians' views of medicare part D

American Journal of Managed Care

Volumn 14, Issue 11 SPEC. ISS., 2008, Pages

  Epstein, Andrew J ^a   Rathore, Sait S ^b   Alexander, G Caleb ^c   Ketcham, Jonathan D ^d  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED STUDY; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MEDICAID; MEDICARE; PHYSICIAN; POPULATION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICAID; MEDICARE PART D; MIDDLE AGED; PHYSICIANS, FAMILY; PRESCRIPTION DRUGS; UNITED STATES;

EID: 56749169623     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Kaiser Family Foundation. National survey of physicians 2006: full topline results. http://www.kff.org/kaiserpolls/7584.cfm. Accessed June 6, 2008.
2. J.D. Power and Associates. J.D. Power and Associates 2006 Medicare Part D beneficiary satisfaction study. September 19, 2006. http://www.jdpower. com/corporate/news/releases/pressrelease.aspx?ID=2006200. Accessed June 6, 2008.
3. KRC Research. Seniors' Opinions About Medicare Rx: Second Year Update. Key Findings, October 2007. http://www.medicaretoday.org/survey.pdf. Accessed June 6, 2008.
4. Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007;26(6):1735-1744.
5. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148(3):169-177.
6. Ketcham JD, Simon KL. Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008;14(11 Spec No.):SP14-SP22.
7. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
8. Tseng C-W, Mangione CM, Brook RH, Keeler E, Dudley RA. Identifying widely covered drugs and drug coverage variation among Medicare Part D formularies. JAMA. 2007;297(23):2596-2602.
9. Hoadley J, Hargrave E, Merrell K, Cubanski J, Neuman T. Benefit Design and Formularies of Medicare Drug Plans: A Comparison of 2006 and 2007 Offerings. November 2006. Kaiser Family Foundation report 7589. http://www.kff.org/medicare/upload/7589.pdf. Accessed June 5, 2008.
10. MedPAC. A Data Book: Healthcare Spending and the Medicare Program. Section 3: Dual-Eligible Beneficiaries. June 2007. http://www.medpac.gov/chapters/Jun07DataBookSec3.pdf. Accessed June 5, 2008.
11. Hall JP, Kurth NK, Moore JM. Transition to Medicare Part D: an early snapshot of barriers experienced by younger dual eligibles with disabilities. Am J Manag Care. 2007;13(1):14-18.
12. King KM, Powner DA. Medicare Part D: Challenges in Enrolling New Dual-Eligible Beneficiaries. May 2007 Government Accounting Agency report GAO-07-272. http://www.gao.gov/new.items/d07272.pdf. Accessed June 5, 2008.
13. Smith V, Gifford K, Kramer S, Elam L. The Transition of Dual Eligibles to Medicare Part D Prescription Drug Coverage: State Actions During Implementation. February 2006. Kaiser Commission on Medicaid and the Uninsured report 7467. http://www.kff.org/medicaid/upload/7467.pdf. Accessed June 5, 2008.
14. Levinson DR. Dual Eligibles' Transition: Part D Formularies' Inclusion of Commonly Used Drugs. January 2006. Department of Health and Human Services, Office of Inspector General report OEI-05-06-00090. oig.hhs.gov/oei/reports/oei-05-06-00090.pdf. Accessed June 6, 2008.
15. West JC, Wilk JE, Muszynzki IL, et al. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. Am J Psychiatry. 2007;164(5):789-796.
16. Florida Agency for Health Care Administration. Florida Medicaid preferred drug program. http://www.fdhc.state.fl.us/Medicaid/Prescribed_Drug/ preferred_drug.shtml. Accessed June 5, 2008.
17. Massachusetts Office of Health and Human Services. MassHealth drug list. http://www.mass.gov/druglist. Accessed June 5, 2008.
18. Texas Health and Human Services Commission. Texas preferred drug list program. http://www.hhsc.state.tx.us/hcf/vdp/pt/PDL_Program.html. Accessed June 5, 2008.
19. North Carolina Medicaid. North Carolina enhanced pharmacy program. http://www.ncmedicaidpbm.com. Accessed June 5, 2008.
20. Wilk JE, West JC, Rae DS, Rubio-Stipec M, Chen JJ, Regier DA. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiatr Serv. 2008;59(1):34-39.
21. Ketcham JD, Epstein AJ. Medicaid preferred drug lists costs to physicians. Med Care. 2008;46(1):9-16.
22. Ketcham JD, Epstein AJ. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives? Pharmacoeconomics. 2006;24(Suppl 3):27-40.
23. Ketcham JD, Ngai JK. How similar are states' Medicaid preferred drug lists? Am J Manag Care. 2008;14(11 Spec No.):SP46-SP52.
24. Hsu J, Fung V, Price M, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299(16):1929-1936.
25. Shrank WH, Fox SA, Kirk A, et al. The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med. 2006;21(4):334-339.
26. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):e283.
27. Shrank WH, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005;11(1):16-22.
28. Hellerstein JK. The importance of the physician in the generic versus trade-name prescription decision. RAND J Econ. 1998;29(1):108-136.
29. Glied S, Zivin JG. How do doctors behave when some (but not all) of their patients are in managed care? J Health Econ. 2002;21(2):337-353.
30. Huskamp HA, Keating NL. The new Medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med. 2005;20(7):662-665.
31. Landen BE, Reschovsky JD, Blumenthal D. Physicians' views of formularies: implications for Medicare drug benefit design. Health Aff (Millwood). 2004;23(1):218-226.
32. Buchsbaum L, Varon J, Kagel E, Boyle RT, McGarvey KC. Perspectives on Medicare Part D and Dual Eligibles: Key Informants' Views From Three States. May 2006. Kaiser Commission on Medicaid and the Uninsured report 7639. http://www.kff.org/medicaid/upload/7639.pdf. Accessed June 5, 2008.
33. Hargrave E, Piya B, Hoadley J, Summer L, Thompson J. Experiences Obtaining Drugs Under Part D: Focus Groups With Beneficiaries, Physicians, and Pharmacists. May 2008. MedPAC report 08-4. http://www.medpac.gov/documents/May08_PartDFocusGroup_CONTRACTOR_JS.pdf. Accessed June 5, 2008.
34. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res. 2001;35(6):1347-1355.
35. Asch DA, Jedrzieski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50(10):1129-1136.